Halozyme Therapeutics stock is trading -27.98% below its average target price of $50.3 after marking a 5.2% during today's afternoon session. Analysts are giving the mid-cap Biotechnology company an average rating of buy and target prices ranging from $28.0 to $72.0 per share.
Halozyme Therapeutics has an average level of shares sold short, at 6.6% of its total share float. The stock's short ratio (also called days to cover) is 6.83. Only 1.0% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Institutional investors own 95.1% of Halozyme Therapeutics's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Halozyme Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Blackrock Inc. | 14% | 18,118,615 | $656,346,800 |
| 2023-09-30 | Vanguard Group Inc | 10% | 13,106,644 | $474,788,158 |
| 2023-09-30 | Artisan Partners Limited Partnership | 6% | 7,712,874 | $279,398,848 |
| 2023-09-30 | State Street Corporation | 5% | 6,209,531 | $224,940,251 |
| 2023-09-30 | Snyder Capital Management, LP | 3% | 4,324,232 | $156,645,297 |
| 2023-09-30 | Macquarie Group Limited | 3% | 3,444,190 | $124,765,777 |
| 2023-09-30 | Alliancebernstein L.P. | 3% | 3,356,776 | $121,599,205 |
| 2023-09-30 | JP Morgan Chase & Company | 2% | 3,163,265 | $114,589,269 |
| 2023-09-30 | Geode Capital Management, LLC | 2% | 2,787,349 | $100,971,713 |
| 2023-09-30 | Marshall Wace LLP | 2% | 2,724,811 | $98,706,274 |
